Skip to search form
Skip to main content
Semantic Scholar's Logo
Create Free Account
You are currently offline. Some features of the site may not work correctly.
National Institutes of Health
Semantic Scholar uses AI to extract papers important to this topic.
A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus
B. M. Tijink
G. V. van Dongen
Clinical Cancer Research
Corpus ID: 2599081
Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine…
HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice
Corpus ID: 208470200
1429 Several anti-tumor antibody-maytansinoid conjugates, commonly called TAPs (tumor-activated prodrugs) are currently under…
Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice
Journal of Pharmacology and Experimental…
Corpus ID: 1660660
The humanized monoclonal antibody maytansinoid conjugate, cantuzumab mertansine (huC242-DM1) that contains on average three to…
Nouvelle formulation stable
Corpus ID: 188582263
L'invention concerne une formulation stable destinee a huC242-DM1, un anticorps conjugue a un agent cytotoxique.
Technology evaluation: C242-DM1, ImmunoGen Inc.
Current opinion in molecular therapeutics
Corpus ID: 22143103
C242-DM1 is a tumor-activated immunotoxin under development by GlaxoSmithKline plc (formerly SmithKline Beecham plc), under…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE